serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetesmellitus. Diabetes Metab Res Rev 1999; 15: 5-12.
109. Collazos J, Genolla J, Ruibal A. Neuron-specific enolase concentrations in serum in benign liver diseases. Clin Chem 1991; 37: 579-81.
110. Massabki PS, Silva NP, Lourenco DM, Andrade LE. Neuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis. J Rheumatol 2003; 30: 2606-12.
111. Petrak J, Ivanek R, Toman O
Roxana Buzas, Alexandru Florin Rogobete, Sonia Elena Popovici, Tudor Mateescu, Teodora Hoinoiu, Virgiliu-Bogdan Sorop, Tiberiu Bratu, Marian Ticlea, Calin Marius Popoiu and Dorel Sandesc
Res. 2010;106:1035-1039. doi: 10.1161/CIRCRESAHA.110.218297.
64. Caporali A, Meloni M, Vo C, et al. Deregulation of microRNA-503 Contributes to DiabetesMellitus-Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia. Circulation. 2011;123:282-291. doi: 10.1161/CIRCULATIONAHA.110.952325.
65. Liu C, Liu N, Cao B, et al. CircRNAs as Potential Biomarkers in Gastrointestinal Tract Tumors : Opportunities and Challenges. Clin Lab. 2018;64:141-145. doi: 10.7754/Clin.Lab.2017.170731.
66. Giden R, Gökdemir MT, Erel Ö, et
Jasenka Gugic, Lorna Zadravec Zaletel and Irena Oblak
31 Stehouwer CD, Yudkin JS, Fioretto P, Nosadini R. How heterogeneous is microalbuminuria in diabetesmellitus? The case for „benign“ and „malignant“ microalbuminuria. Nephrol Dial Transplant 1998; 13 : 2751-4. 10.1093/ndt/13.11.2751
Stehouwer CD Yudkin JS Fioretto P Nosadini R How heterogeneous is microalbuminuria in diabetesmellitus? The case for „benign“ and „malignant“ microalbuminuria Nephrol Dial Transplant 1998 13 2751 4
32 Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts
Alenka Matjasic, Mara Popovic, Bostjan Matos and Damjan Glavac
inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer Oncotarget 2016 7 44505 44521 10.18632/oncotarget.9887
48 Qu X, Yu H, Jia B, Yu X, Cui Q, Liu Z, et al., Association of downregulated HDAC 2 with the impaired mitochondrial function and cytokine secretion in the monocytes/macrophages from gestational diabetesmellitus patients. Cell Biol Int 2016; 40 : 642-51. 10.1002/cbin.10598
Qu X, Yu H, Jia B, Yu X, Cui Q, Liu Z, et al Association of downregulated HDAC 2 with the impaired
systemic diffuse large B cell lymphoma (DLBCL) presented to our oncology clinic in the beginning of September 2013 with high fever, headache and altered mental status.
Her past medical history included arterial hypertension and type 2 diabetesmellitus, both well controlled with medications. Since 2010, she was treated for marginal zone B cell lymphoma stage IV A, involving the spleen, bone marrow and lymph nodes. A splenectomy was performed in July 2011. At that time, no other treatment was administered due to clinical remission. In August 2012, the disease progressed
Gabrijela Brzan Simenc, Jana Ambrozic, Katja Prokselj, Natasa Tul, Marta Cvijic, Tomislav Mirkovic, Helmut Karl Lackner and Miha Lucovnik
diabetesmellitus. None had prior ocular surgery or ocular trauma. Median maternal age was 31 years (range 21–44 years); median maternal pre-pregnancy body mass index was 23 kg/m 2 (range 19–32 kg/m 2 ), and median gestational age at study inclusion was 32 5/7 weeks (range 22 3/7–39 4/7 weeks). Twenty-three (77%) patients were nulliparous. Severe features of preeclampsia meeting the inclusion criteria were: hypertension in all 30 cases, headache in 14 (47%) cases, visual disturbances in four (13%) cases, elevated liver enzymes in 10 (33%) cases, thrombocytopenia in
Noora Al-Hammadi, Palmira Caparrotti, Carole Naim, Jillian Hayes, Katherine Rebecca Benson, Ana Vasic, Hissa Al-Abdulla, Rabih Hammoud, Saju Divakar and Primoz Petric
. Patients with cardiac V25Gy ≥ 5% on FB treatment plan were offered V-DIBH. In addition, selected cases with lower V25Gy were entered on the V-DIBH protocol. This selection was performed at discretion of the treating radiation oncologist by considering patient-related factors such as age, pre-existent ischemic cardiac events and other co-morbidities, application of cardio-toxic medications, history of smoking, diabetesmellitus, hyperlipidemia and arterial hypertension.
Our V-DIBH approach was adapted from the technique used in the UK HeartSpare study and was based on